Evidence map›Paper›PMID 42447419›Full record

Trial reportJournal of clinical oncology : official journal of the American Society of Clinical Oncology2026

Clinical and Psychological Outcomes After Monoclonal Gammopathy Screening: A Population-Based Screening Study and Subsequent Randomized Trial of Follow-Up.

Sæmundur Rögnvaldsson, Sigrún Thorsteinsdóttir, Elias Eythorsson, Inga Dröfn Wessman, Gudrun Asta Sigurdardottir, Brynjar Vidarsson, Pall T Onundarson, Bjarni Agnarsson, Margret Sigurdardottir, Isleifur Olafsson and 19 more

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03327597 (Iceland Screens, Treats or Prevents Multiple Myeloma), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03327597 naactive not recruitingnot on this map

Iceland Screens, Treats or Prevents Multiple Myeloma

TypeinterventionalSponsorUniversity of IcelandRan2016 to 2026Enrolled80,761ConditionsMonoclonal Gammopathy of Undetermined SignificanceArmsClinical follow-up 1, Mental Health and Quality of Life questionnaire, Standard follow-up or treatment., Clinical follow-up 2, Clinical follow-up 3
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors.

Sæmundur RögnvaldssonFaculty of Medicine, University of Iceland, Reykjavik, Iceland.ORCID 0000-0003-2162-8414
Sigrún ThorsteinsdóttirFaculty of Medicine, University of Iceland, Reykjavik, Iceland.ORCID 0000-0001-5017-3530
Elias EythorssonFaculty of Medicine, University of Iceland, Reykjavik, Iceland.ORCID 0000-0002-0277-7628
Inga Dröfn WessmanFaculty of Psychology, University of Iceland, Reykjavik, Iceland.ORCID 0000-0002-2609-5664
Gudrun Asta SigurdardottirFaculty of Medicine, University of Iceland, Reykjavik, Iceland.
Brynjar VidarssonLandspitali University Hospital, Reykjavik, Iceland.
Pall T OnundarsonFaculty of Medicine, University of Iceland, Reykjavik, Iceland.
Bjarni AgnarssonFaculty of Medicine, University of Iceland, Reykjavik, Iceland.ORCID 0000-0001-7721-9965
Margret SigurdardottirLandspitali University Hospital, Reykjavik, Iceland.
Isleifur OlafssonLandspitali University Hospital, Reykjavik, Iceland.
Ingunn ThorsteinsdottirLandspitali University Hospital, Reykjavik, Iceland.
Andri Steinthor BjornssonFaculty of Psychology, University of Iceland, Reykjavik, Iceland.ORCID 0000-0003-0307-2512
Jon Thorir OskarssonFaculty of Medicine, University of Iceland, Reykjavik, Iceland.ORCID 0000-0002-9201-1166
Andri OlafssonFaculty of Medicine, University of Iceland, Reykjavik, Iceland.ORCID 0000-0002-7381-8431
Gauti GislasonFaculty of Medicine, University of Iceland, Reykjavik, Iceland.
Ingigerdur SverrisdottirSahlgrenska University Hospital, Gothenburg, Sweden.
Thorir E LongFaculty of Medicine, University of Iceland, Reykjavik, Iceland.ORCID 0000-0003-2377-7886
Elfa Rún GuðmundsdóttirFaculty of Medicine, University of Iceland, Reykjavik, Iceland.
Asdis Rosa ThordardottirFaculty of Medicine, University of Iceland, Reykjavik, Iceland.ORCID 0009-0009-0430-7302
Asbjorn JonssonAkureyri Hospital, Akureyri, Iceland.ORCID 0000-0002-2374-9773
Runolfur PalssonFaculty of Medicine, University of Iceland, Reykjavik, Iceland.ORCID 0000-0001-6763-1702
Olafur S IndridasonLandspitali University Hospital, Reykjavik, Iceland.ORCID 0000-0001-8509-6598
Malin HultcrantzMyeloma Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY.ORCID 0000-0002-9045-6495
Brian G M DurieSamuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Outpatient Cancer Center, Los Angeles, CA.
Stephen J HardingBinding Site Group Ltd Part of Thermo Fisher Scientific, Birmingham, United Kingdom.
Thor AspelundSahlgrenska University Hospital, Gothenburg, Sweden.ORCID 0000-0002-7998-5433
Ola LandgrenDivision of Myeloma Program, Department of Medicine, University of Miami, Sylvester Comprehensive Cancer Center, Miami, FL.ORCID 0000-0001-6485-4839
Thorvardur Jon LoveFaculty of Medicine, University of Iceland, Reykjavik, Iceland.ORCID 0000-0002-2680-6120
Sigurdur Y KristinssonFaculty of Medicine, University of Iceland, Reykjavik, Iceland.ORCID 0000-0002-4964-7476

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Multiple myeloma (MM) and related malignancies develop from an asymptomatic precursor condition, monoclonal gammopathy of undetermined significance (MGUS), detectable via blood testing. The benefits and harms of population-based MGUS screening remain uncertain. We conducted a nationwide screening study for monoclonal gammopathies and a randomized trial of follow-up strategies in Iceland (Iceland Screens, Treats, or Prevents Multiple Myeloma; ClinicalTrials.gov identifier: NCT03327597). In total, 75,422 (53% of those invited) were screened and those with MGUS (n = 3,541) were randomly assigned to no notification (arm 1), guideline-based follow-up (arm 2), or intensified follow-up (arm 3). Progression, symptom burden, and psychological well-being were compared between the control arm (arm 1) and intervention arms (arms 2 and 3). After a median follow-up of 4.5 years, screening led to a 27-fold increase in the detection of smoldering MM (8.6%

Indexed as

Mass ScreeningMonoclonal Gammopathy of Undetermined SignificanceMultiple MyelomaAgedDisease ProgressionFemaleFollow-Up StudiesHumansIcelandMaleMiddle Aged

Identifiers

PMID42447419
PMCPMC13668039

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.